Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Novo Nordisk's CEO took the Washington hot seat over Ozempic prices. 3 takeaways from his testimony
CEO Lars Fruergaard Jørgensen agreed today, during a Senate committee hearing, to sit down with lawmakers and pharmacy benefit managers (PBMs) to look into the possibility of cutting list prices for the company’s popular diabetes and weight-loss drugs.
‘You’re hiding behind your opaqueness’: Senators question Novo Nordisk CEO over high cost of Ozempic, Wegovy
Bipartisan lawmakers grilled Novo Nordisk CEO Lars Fruergaard Jørgensen in a Senate hearing in an attempt to pick apart the high cost of GLP-1 drugs.
Novo Nordisk CEO Grilled by Congress Over Price of Ozempic
During a tense hearing before a Senate committee on Tuesday, Novo Nordisk CEO Lars Fruergaard Jørgensen faced tough questions over the company's high prices for its blockbuster drugs Ozempic and Wegovy.
'Stop Ripping Us Off.' Senate Grills Novo Nordisk on High Prices of Weight Loss Drugs Wegovy and Ozempic in US.
Novo Nordisk CEO Lars Fruergaard Jørgensen faced Senate scrutiny over the high prices of Wegovy and Ozempic as U.S. demand surges. While Jørgensen did not commit to lowering prices, he was willing to work on policy solutions to reduce prescription drug costs.
With Novo CEO on the hot seat at Senate hearing, PBMs and insurance concerns get the spotlight
When government officials and politicians scrutinize high U.S. drug prices, the role of insurers and pharmacy benefit managers (PBMs) often commands at least some of the attention. | At the Senate committee hearing on Novo Nordisk's prices for Ozempic and Wegovy,
Ozempic CEO agrees to discuss lower prices for blockbuster weight loss drugs
Is Ozempic and Wegovy maker Novo Nordisk helping Americans save taxpayer money or ripping them off? The company's CEO testified on Capitol Hill Tuesday.
Novo Nordisk CEO grilled over steep weight loss drug costs
Novo Nordisk CEO Lars Fruergaard Jørgensen testified before the Senate Health, Education, Labor and Pension committee on Tuesday.
Novo CEO, Sanders to Face Off Over US Prices for Ozempic and Wegovy
In a high-profile showdown Tuesday with Sen. Bernie Sanders’ Senate health committee, Novo Nordisk CEO Lars Fruergaard Jørgensen will be asked to defend the drugs’ U.S. monthly list prices of $969 and $1,
Senators press Novo Nordisk CEO on why Ozempic and Wegovy cost less abroad
Weight-loss drugs sell in Europe for a fraction of what they cost in the United States, a pattern that is typical for brand-name prescriptions.
Why does Ozempic cost so much? Senators grilled Novo Nordisk CEO for answers.
Novo Nordisk CEO grilled over company's pricing for the diabetes drug Ozempic and the weight-loss drug Wegovy.
Bernie Sanders grills Novo Nordisk CEO on price of Ozempic, other weight-loss drugs
Sen. Bernie Sanders grilled Novo Nordisk's CEO Lars Jorgensen over the cost of the company's weight loss and diabetes medications, Ozempic and Wegovy.
WBIW
2d
Braun to Novo Nordisk CEO: “Why are Americans paying more for the same drug?”
WASHINGTON—U.S. Senator Mike Braun questioned Novo Nordisk CEO, Lars Fruergaard Jørgensen, at the Senate Health, Education, ...
BioSpace
12h
Lilly Is Not ‘Feeling the Bern’ on Drug Prices Like Novo: Why the Double Standard?
Sen. Bernie Sanders’ aggressive targeting of Danish drugmaker Novo Nordisk’s Ozempic and Wegovy pricing, and not Eli Lilly’s ...
NBC DFW
4d
Maker of Ozempic and Wegovy faces grilling over high cost of weight loss drugs
The chief executive of the drugmaker Novo Nordisk,
Lars
Fruergaard
Jørgensen
, is scheduled to face tough questions ...
3d
Ozempic maker to testify before Senate committee on weight loss drug prices
Novo Nordisk CEO Lars Fruergaard Jørgensen is testifying before the Senate Health, Education, Labor and Pension committee on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback